Evidence map›Paper›PMID 33814500›Full record

ArticleInternal medicine (Tokyo, Japan)2021

BCR/ABL1-positive B-lymphoblastic Lymphoma Successfully Treated with Dasatinib-combined Chemotherapy.

Chika Yamada, Yoshimitsu Shimomura, Kimimori Kamijyo, Madoka Kanda-Kato, Satoshi Yoshioka, Daisuke Yamashita, Takayuki Ishikawa

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Case Report: Management of aFrontiers in medicine · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Chika YamadaDepartment of Hematology, Kobe City Medical Center General Hospital, Japan.
Yoshimitsu ShimomuraDepartment of Hematology, Kobe City Medical Center General Hospital, Japan.
Kimimori KamijyoDepartment of Hematology, Kobe City Medical Center General Hospital, Japan.
Madoka Kanda-KatoDepartment of Hematology, Kobe City Medical Center General Hospital, Japan.
Satoshi YoshiokaDepartment of Hematology, Kobe City Medical Center General Hospital, Japan.
Daisuke YamashitaDepartment of Pathology, Kobe City Medical Center General Hospital, Japan.
Takayuki IshikawaDepartment of Hematology, Kobe City Medical Center General Hospital, Japan.
Kobe City Medical Center General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We herein report a rare case of BCR-ABL1-positive B-lymphoblastic lymphoma (B-LBL). An 18-year-old woman had a history of persistent left-sided chest pain. Positron emission tomography showed increased metabolic activity in the fifth rib, duodenum, and pancreas. The pathological findings of the pancreas, duodenum, and bone marrow confirmed the diagnosis of B-LBL. Polymerase chain reaction of duodenum and bone marrow also revealed a minor BCR-ABL1 fusion gene. She was diagnosed with BCR-ABL1-positive B-LBL and administered dasatinib and prednisolone. She achieved complete remission two weeks after the initiation of the treatment. She received stem cell transplantation after consolidation chemotherapy and sustained complete remission.

Indexed as

Fusion Proteins, bcr-ablPrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentDasatinibFemaleHumansProtein Kinase InhibitorsTomography, X-Ray ComputedDasatinibFusion Proteins, bcr-ablProtein Kinase InhibitorsBCR-ABL1B-lymphoblastic lymphomadasatinibtyrosine kinase inhibitors

Identifiers

PMID33814500
PMCPMC8545644
OpenAlexW3149976748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.